Member Info for Timster

Size buyers in charge, bid being lifted, 90/ 100' 104& 110# and 120/ in charge. Very interesting finish with AACR in April.

I've been running several algorithms through the magic calculator assuming .

Using the standard Novartis calculation that I note on page 438 of the bid currently being put together I have a valuation of £26.75 per share. This sounds low to me but I've checked several times and the magic calculator cannot be wrong (much like the horizon system).

I've published my calculations on www.twohundredpoundsexchi-nah.com/magiccalc

Feel free to check the workings. There are also some theories on who Hurstbot is on the Hurstbot tab but these are highly complex.

It's telling DTW, no one knows how he knows so much and hides in plain sight.

The amount of deals being inked you won't believe all will be revealed on the 29th of February.

My buy showing as a sell

Can't buy on HL

Worth remembering with an uptick in M&A that Avacta will be bought for £200 ex chi-nah during AACR

Small word of caution though, it won't happen until we see that all important sujood post.

It's obvious really the silence can only mean one thing and it's this

I suspect you too watching.

Don't worry sheppy your 500k will be worth millions by Thursday!!

And if it's not then no worries as it's completely fictional anyway.

AACR in April

Looks like good news on the way, up 0.48% start of the rerate

🐶💩🪨🦷 and his fluffers have done very well out of avacta I'd imagine.

It's bonkers, pre|CISION works in a sensible market that would be seen as very valuable, but not on AIM

All about ADC's currently. BUT whoever licenses or purchases pre|CISION they get something easier to manufacture and exquisitely targeted.

Quote from the Q&A:

Compared with an ADC, which requires production of both the antibody and warhead, their conjugation (linking together) and then purification of the ADC from the unlinked components in the mixture, the cost of production of a pre|CISION chemotherapy is considerably lower.

pre|CISION addresses some challenges that ADCs face, namely: ADCs need to target an internalising tumour biomarker, expressed at very high levels on the surface of the tumour cell, and this affects the amount of drug that can be got into the cancer cells to kill them whereas pre|CISION therapies do not need to be internalised to release the drug. By targeting release of the payload in the tumour microenvironment, there will be a bystander effect i.e. all cells within the vicinity of the payload will be killed. ADCs are, in general, complex and expensive to manufacture, whereas pre|CISION chemotherapies are relatively simple and affordable. There is therefore scope for both approaches to coexist.

Are you aware of the clinical trials Avacta are pretending to partake in?

Could they have some effect?

Are you aware the the pre|CISION platform works and there is commercial interest? Will that have any effect

Probably best to concentrate on the lft though

I thought national twat day was yesterday. After it's roaring success it seems it's been extended to a weekend twatfest.

There's a 20p placing coming...

83p would be ridiculously overvalued

Is Amtagvi the way the yanks spell Abakta?

WHY has this only been communicated to you??? I presume during a seal clubbing expedition arranged by Al?

I am furious..... I've written a strongly worded email to concilium 🤬🤬

Is there time for phase 1 and 2 by AACR??

Exciting times!!!